
Global mRNA Vaccines & Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
Description
Summary
mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
According to APO Research, The global mRNA Vaccines & Therapeutics market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for mRNA Vaccines & Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for mRNA Vaccines & Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for mRNA Vaccines & Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for mRNA Vaccines & Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of mRNA Vaccines & Therapeutics include Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA and Ethris, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for mRNA Vaccines & Therapeutics, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of mRNA Vaccines & Therapeutics, also provides the sales of main regions and countries. Of the upcoming market potential for mRNA Vaccines & Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the mRNA Vaccines & Therapeutics sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global mRNA Vaccines & Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for mRNA Vaccines & Therapeutics sales, projected growth trends, production technology, application and end-user industry.
mRNA Vaccines & Therapeutics Segment by Company
Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
eTheRNA
Ethris
Tiba Biotechnology
mRNA Vaccines & Therapeutics Segment by Type
Infectious Disease Vaccines
Cancer Vaccines
mRNA Vaccines & Therapeutics Segment by Application
Infectious Disease
Cancer
mRNA Vaccines & Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Vaccines & Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of mRNA Vaccines & Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Vaccines & Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the mRNA Vaccines & Therapeutics market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of mRNA Vaccines & Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of mRNA Vaccines & Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of mRNA Vaccines & Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
According to APO Research, The global mRNA Vaccines & Therapeutics market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for mRNA Vaccines & Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for mRNA Vaccines & Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for mRNA Vaccines & Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for mRNA Vaccines & Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of mRNA Vaccines & Therapeutics include Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA and Ethris, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for mRNA Vaccines & Therapeutics, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of mRNA Vaccines & Therapeutics, also provides the sales of main regions and countries. Of the upcoming market potential for mRNA Vaccines & Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the mRNA Vaccines & Therapeutics sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global mRNA Vaccines & Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for mRNA Vaccines & Therapeutics sales, projected growth trends, production technology, application and end-user industry.
mRNA Vaccines & Therapeutics Segment by Company
Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
eTheRNA
Ethris
Tiba Biotechnology
mRNA Vaccines & Therapeutics Segment by Type
Infectious Disease Vaccines
Cancer Vaccines
mRNA Vaccines & Therapeutics Segment by Application
Infectious Disease
Cancer
mRNA Vaccines & Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Vaccines & Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of mRNA Vaccines & Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Vaccines & Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the mRNA Vaccines & Therapeutics market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of mRNA Vaccines & Therapeutics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of mRNA Vaccines & Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of mRNA Vaccines & Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
190 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global mRNA Vaccines & Therapeutics Market Size, 2020 VS 2024 VS 2031
- 1.3 Global mRNA Vaccines & Therapeutics Market Size Estimates and Forecasts (2020-2031)
- 1.4 Global mRNA Vaccines & Therapeutics Sales Estimates and Forecasts (2020-2031)
- 1.5 Global mRNA Vaccines & Therapeutics Market Average Price (2020-2031)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 2 Global mRNA Vaccines & Therapeutics Market Dynamics
- 2.1 mRNA Vaccines & Therapeutics Industry Trends
- 2.2 mRNA Vaccines & Therapeutics Industry Drivers
- 2.3 mRNA Vaccines & Therapeutics Industry Opportunities and Challenges
- 2.4 mRNA Vaccines & Therapeutics Industry Restraints
- 3 mRNA Vaccines & Therapeutics Market by Manufacturers
- 3.1 Global mRNA Vaccines & Therapeutics Revenue by Manufacturers (2020-2025)
- 3.2 Global mRNA Vaccines & Therapeutics Sales by Manufacturers (2020-2025)
- 3.3 Global mRNA Vaccines & Therapeutics Average Sales Price by Manufacturers (2020-2025)
- 3.4 Global mRNA Vaccines & Therapeutics Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
- 3.5 Global mRNA Vaccines & Therapeutics Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global mRNA Vaccines & Therapeutics Manufacturers, Product Type & Application
- 3.7 Global mRNA Vaccines & Therapeutics Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global mRNA Vaccines & Therapeutics Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 mRNA Vaccines & Therapeutics Players Market Share by Revenue in 2024
- 3.8.3 2024 mRNA Vaccines & Therapeutics Tier 1, Tier 2, and Tier 3
- 4 mRNA Vaccines & Therapeutics Market by Type
- 4.1 mRNA Vaccines & Therapeutics Type Introduction
- 4.1.1 Infectious Disease Vaccines
- 4.1.2 Cancer Vaccines
- 4.2 Global mRNA Vaccines & Therapeutics Sales by Type
- 4.2.1 Global mRNA Vaccines & Therapeutics Sales by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global mRNA Vaccines & Therapeutics Sales by Type (2020-2031)
- 4.2.3 Global mRNA Vaccines & Therapeutics Sales Market Share by Type (2020-2031)
- 4.3 Global mRNA Vaccines & Therapeutics Revenue by Type
- 4.3.1 Global mRNA Vaccines & Therapeutics Revenue by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global mRNA Vaccines & Therapeutics Revenue by Type (2020-2031)
- 4.3.3 Global mRNA Vaccines & Therapeutics Revenue Market Share by Type (2020-2031)
- 5 mRNA Vaccines & Therapeutics Market by Application
- 5.1 mRNA Vaccines & Therapeutics Application Introduction
- 5.1.1 Infectious Disease
- 5.1.2 Cancer
- 5.2 Global mRNA Vaccines & Therapeutics Sales by Application
- 5.2.1 Global mRNA Vaccines & Therapeutics Sales by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global mRNA Vaccines & Therapeutics Sales by Application (2020-2031)
- 5.2.3 Global mRNA Vaccines & Therapeutics Sales Market Share by Application (2020-2031)
- 5.3 Global mRNA Vaccines & Therapeutics Revenue by Application
- 5.3.1 Global mRNA Vaccines & Therapeutics Revenue by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global mRNA Vaccines & Therapeutics Revenue by Application (2020-2031)
- 5.3.3 Global mRNA Vaccines & Therapeutics Revenue Market Share by Application (2020-2031)
- 6 Global mRNA Vaccines & Therapeutics Sales by Region
- 6.1 Global mRNA Vaccines & Therapeutics Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global mRNA Vaccines & Therapeutics Sales by Region (2020-2031)
- 6.2.1 Global mRNA Vaccines & Therapeutics Sales by Region (2020-2025)
- 6.2.2 Global mRNA Vaccines & Therapeutics Sales Forecasted by Region (2025-2030)
- 6.3 North America
- 6.3.1 North America mRNA Vaccines & Therapeutics Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.3.2 North America mRNA Vaccines & Therapeutics Sales by Country (2020-2031)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe mRNA Vaccines & Therapeutics Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.4.2 Europe mRNA Vaccines & Therapeutics Sales by Country (2020-2031)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific mRNA Vaccines & Therapeutics Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.5.2 Asia Pacific mRNA Vaccines & Therapeutics Sales by Country (2020-2031)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa mRNA Vaccines & Therapeutics Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.6.2 South America, Middle East and Africa mRNA Vaccines & Therapeutics Sales by Country (2020-2031)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
- 7 Global mRNA Vaccines & Therapeutics Revenue by Region
- 7.1 Global mRNA Vaccines & Therapeutics Revenue by Region
- 7.1.1 Global mRNA Vaccines & Therapeutics Revenue by Region: 2020 VS 2024 VS 2031
- 7.1.2 Global mRNA Vaccines & Therapeutics Revenue by Region (2020-2025)
- 7.1.3 Global mRNA Vaccines & Therapeutics Revenue by Region (2026-2031)
- 7.1.4 Global mRNA Vaccines & Therapeutics Revenue Market Share by Region (2020-2031)
- 7.2 North America
- 7.2.1 North America mRNA Vaccines & Therapeutics Revenue (2020-2031)
- 7.2.2 North America mRNA Vaccines & Therapeutics Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.3 Europe
- 7.3.1 Europe mRNA Vaccines & Therapeutics Revenue (2020-2031)
- 7.3.2 Europe mRNA Vaccines & Therapeutics Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific mRNA Vaccines & Therapeutics Revenue (2020-2031)
- 7.4.2 Asia-Pacific mRNA Vaccines & Therapeutics Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa mRNA Vaccines & Therapeutics Revenue (2020-2031)
- 7.5.2 South America, Middle East and Africa mRNA Vaccines & Therapeutics Revenue Share by Country: 2020 VS 2024 VS 2031
- 8 Company Profiles
- 8.1 Moderna Therapeutics
- 8.1.1 Moderna Therapeutics Comapny Information
- 8.1.2 Moderna Therapeutics Business Overview
- 8.1.3 Moderna Therapeutics mRNA Vaccines & Therapeutics Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.1.4 Moderna Therapeutics mRNA Vaccines & Therapeutics Product Portfolio
- 8.1.5 Moderna Therapeutics Recent Developments
- 8.2 CureVac
- 8.2.1 CureVac Comapny Information
- 8.2.2 CureVac Business Overview
- 8.2.3 CureVac mRNA Vaccines & Therapeutics Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.2.4 CureVac mRNA Vaccines & Therapeutics Product Portfolio
- 8.2.5 CureVac Recent Developments
- 8.3 Translate Bio
- 8.3.1 Translate Bio Comapny Information
- 8.3.2 Translate Bio Business Overview
- 8.3.3 Translate Bio mRNA Vaccines & Therapeutics Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.3.4 Translate Bio mRNA Vaccines & Therapeutics Product Portfolio
- 8.3.5 Translate Bio Recent Developments
- 8.4 BioNTech
- 8.4.1 BioNTech Comapny Information
- 8.4.2 BioNTech Business Overview
- 8.4.3 BioNTech mRNA Vaccines & Therapeutics Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.4.4 BioNTech mRNA Vaccines & Therapeutics Product Portfolio
- 8.4.5 BioNTech Recent Developments
- 8.5 Sangamo Therapeutics
- 8.5.1 Sangamo Therapeutics Comapny Information
- 8.5.2 Sangamo Therapeutics Business Overview
- 8.5.3 Sangamo Therapeutics mRNA Vaccines & Therapeutics Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.5.4 Sangamo Therapeutics mRNA Vaccines & Therapeutics Product Portfolio
- 8.5.5 Sangamo Therapeutics Recent Developments
- 8.6 Argos Therapeutics
- 8.6.1 Argos Therapeutics Comapny Information
- 8.6.2 Argos Therapeutics Business Overview
- 8.6.3 Argos Therapeutics mRNA Vaccines & Therapeutics Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.6.4 Argos Therapeutics mRNA Vaccines & Therapeutics Product Portfolio
- 8.6.5 Argos Therapeutics Recent Developments
- 8.7 In-Cell-Art
- 8.7.1 In-Cell-Art Comapny Information
- 8.7.2 In-Cell-Art Business Overview
- 8.7.3 In-Cell-Art mRNA Vaccines & Therapeutics Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.7.4 In-Cell-Art mRNA Vaccines & Therapeutics Product Portfolio
- 8.7.5 In-Cell-Art Recent Developments
- 8.8 eTheRNA
- 8.8.1 eTheRNA Comapny Information
- 8.8.2 eTheRNA Business Overview
- 8.8.3 eTheRNA mRNA Vaccines & Therapeutics Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.8.4 eTheRNA mRNA Vaccines & Therapeutics Product Portfolio
- 8.8.5 eTheRNA Recent Developments
- 8.9 Ethris
- 8.9.1 Ethris Comapny Information
- 8.9.2 Ethris Business Overview
- 8.9.3 Ethris mRNA Vaccines & Therapeutics Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.9.4 Ethris mRNA Vaccines & Therapeutics Product Portfolio
- 8.9.5 Ethris Recent Developments
- 8.10 Tiba Biotechnology
- 8.10.1 Tiba Biotechnology Comapny Information
- 8.10.2 Tiba Biotechnology Business Overview
- 8.10.3 Tiba Biotechnology mRNA Vaccines & Therapeutics Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.10.4 Tiba Biotechnology mRNA Vaccines & Therapeutics Product Portfolio
- 8.10.5 Tiba Biotechnology Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 mRNA Vaccines & Therapeutics Value Chain Analysis
- 9.1.1 mRNA Vaccines & Therapeutics Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 mRNA Vaccines & Therapeutics Production Mode & Process
- 9.2 mRNA Vaccines & Therapeutics Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 mRNA Vaccines & Therapeutics Distributors
- 9.2.3 mRNA Vaccines & Therapeutics Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.